Accelerating the discovery and development of antibody drugs is an eternal theme in the biopharmaceutical field. While traditional R&D processes are still struggling with lengthy delivery cycles and high costs, GentleGen——a leading genetic technology application platform——has completely broken this deadlock with its self-developed GentSynExp 3.0 G-Lab fully automated platform.

Embracing "black-light factories," directly addressing the "dual pain points" of R&D cycles and delivery quality

In today's fiercely competitive antibody drug R&D track, speed and quality often directly determine whether an innovative molecule can capture the market first. Traditional gene synthesis and antibody expression services heavily rely on manual operations and multi-platform collaboration, with fragmented processes and inconsistent quality control standards that long limit R&D progress. Manual operations not only face efficiency bottlenecks but are also prone to delivery delays and quality fluctuations caused by human error.

GentleGen was the first to introduce "automation + intelligence" technology, building a one-stop solution covering gene design, synthesis, validation, protein expression, and antibody development. The company's self-developed AI smart laboratory integrates AI technology into every key technical stage, from primer fragment design to PCR amplification and assembly, greatly freeing up human resources and significantly improving the accuracy and efficiency of gene synthesis.

At the same time, the company focuses on foundational technological innovation and has successfully built a fully automated gene technology application platform. Focusing on the critical transition of gene technology from the laboratory to industrialization, it provides practical solutions for large-scale cost reduction and efficiency improvement in the industry.

This top-down automation revolution not only shortens the R&D cycle, but also delivers products of exceptional quality and high stability to customers.

G-Lab 3.0: Pressing the "fast-forward button" for antibody drug development

GentleGen's G-Lab 3.0 fully automated gene antibody platform is undoubtedly its core "trump card" in fierce market competition. This platform innovatively adopts the "black factory" automated module production model, integrating AI intelligent algorithms and information management systems, truly achieving a full-chain unmanned operation from gene design to antibody delivery, minimizing human error rates.

In terms of delivery cycles, the G-Lab 3.0 platform has achieved an astonishing "GentleGen Speed." Relying on 7×24/7 uninterrupted synthesis capability, GentleGen can complete the delivery from gene synthesis to antibody supernatant in as little as 10 working days, significantly shortening delivery times compared to industry norms. To obtain a cloning vector, it takes as little as 72 hours to complete.

In terms of overall production efficiency, the platform can process over 3,000 samples at once, with daily reaction throughput smoothly exceeding ten thousand. Such powerful comprehensive delivery capabilities not only effectively empower companies to accelerate early antibody discovery, but also greatly promote the efficient transformation of recombinant protein and antibody drugs from concept to industrialization.

Comprehensive technical advantages across the entire chain, establishing a secure quality moat for customers

GentleGen does not pursue efficiency alone; it also adheres to strict standards for product quality. For complex gene sequences, the platform uses its independently developed intelligent codon optimization algorithm and sequence assembly technology to overcome conventional synthesis challenges such as high GC/AT content and repeat sequences, ensuring a first-time synthesis success rate of up to 99% and sequence accuracy of 99.9%.

In addition, GentleGen strictly ensures product quality through multi-dimensional, full-process quality control, guaranteeing the stability of every batch. For example, the production process meets stringent quality control standards such as superhelical plasmid content above 90%, delivered antibody product purity greater than or equal to 95%, endotoxin content below 1 EU/mg, and antibody delivery concentration above 1 mg/ml, ensuring the final product meets more stringent downstream application requirements for mammalian cell transfection, virus packaging, functional validation, and other demanding applications.

On the cost side, GentleGen leverages the advantages of highly scaled and automated integration to reduce labor and reagent costs, while also significantly lowering customers' early screening costs. IgG monoclonal antibody gene synthesis services cost only 259 yuan per tube, and VHH nanobody gene synthesis services only 129 yuan per tube. The unit price includes the 800μl antibody supernatant included with the product. After receiving them, customers can directly use them for downstream experiments such as functional validation and affinity evaluation, eliminating additional purification steps and further accelerating the transition from gene sequence to functional validation, buying valuable time for the project team to seize the R&D advantage.

Forward-looking strategic layout comprehensively supports the biopharmaceutical industry

In addition to core services for gene synthesis and antibody expression, GentleGen has also deeply deployed a series of forward-looking gene technology services, empowering the entire life sciences industry chain.

The company owns two major sub-brands: GentleGen and GenTrobotics, with oligonucleotide production capabilities ranging from NMOL to UMOL, covering diverse scenarios from high-throughput scientific research to preclinical applications.

At the same time, GentleGen has launched a biopharmaceutical safety evaluation service based on NGS high-throughput sequencing, which not only identifies the background of hybrid cell lines but also enables precise single-base level localization of integration sites, ensuring high stability and safety in cell lines and drug manufacturing processes, and safeguarding IND applications and drug launches for innovative drug companies.

Leveraging its strong capabilities in automation, intelligence, and biotechnology, the company has established a one-stop gene service platform covering gene synthesis, sequencing, editing, and expression.

GentleGen's G-Lab fully automated gene antibody platform will continuously inject strong momentum into your biopharmaceutical innovation projects through cutting-edge automation technology, rapid delivery capabilities, and rigorous safety and quality control! GentleGen can provide related services. For detailed information about related services, please send an email to marketing@gentlegen.com.